香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY （股份代號：9966） 自願公告 KN026新輔助治療HER2陽性乳腺癌III期臨床研究達到主要終點 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，旨在知會本集團股東（「股東」）及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，與石藥集團有限公司（「石藥集 團」）（股份代號：1093）附屬公司上海津曼特生物科技有限公司（「津曼特生物」） 合作開發的KN026聯合注射用多西他賽（白蛋白結合型）(HB1801)用於人表皮生長 因子受體2（「HER2」）陽性（「HER2陽性」）乳腺癌（「BC」）新輔助治療的III期臨床 研究（研究代號：KN026-004），達到預先設定的總體病理完全緩解率（「tpCR」） 的主要終點，結果具有顯著的統計學和臨床意義。 BC是中國女性發病率最高的惡性腫瘤，其中HER2 ...

Summary of the Conference Call for 康宁杰瑞 Company Overview - **Company**: 康宁杰瑞 - **Core Products**: - KN026 (HER2 bispecific antibody) - KN003 (HER2 bispecific ADC) - KN016 (TROP2/HER3 bispecific ADC) - KN033 (first IO+ADC subcutaneous formulation) - Early pipeline products: KN022, KN027, KN021 Key Points and Arguments Product Development and Clinical Trials - **KN026**: NDA for second-line gastric cancer accepted, expected approval in H1 2026; overall survival (OS) data nearing 20 months, significantly better than existing therapies [2][4] - **KN003**: Phase III data for second-line breast cancer expected in 2026; ORR close to 70% in colorectal cancer and 63.8% in platinum-resistant ovarian cancer, with safety profile superior to T-DM1 [2][4] - **KN016**: Focused on lung and breast cancer, Phase III for triple-negative breast cancer (TNBC) initiated, with HR+ breast cancer data expected in 2026 [2][4] - **KN033**: Progressing well, targeting second-line cervical/endometrial cancer, EOP2 submission expected in 2026 [2][4] - **Early Pipeline**: KN022, KN027, and KN021 in dose escalation, with multiple POC data updates anticipated in 2026 [2][4] Financial Performance - **2025 Financials**: Total revenue of 566 million CNY, with product license revenue at 73%; R&D expenses reached 572 million CNY, a five-year high; cash reserves at 1.35 billion CNY; loss of approximately 100 million CNY due to increased clinical R&D costs [4][27] - **2026 Outlook**: Key year with expectations for the second product launch and third product submission, alongside multiple overseas IND applications [2][4] Strategic Partnerships and Market Position - **Overseas Strategy**: Shiyao responsible for domestic sales, while the company retains overseas rights; plans to leverage strong Phase III data for potential business development or direct EU applications [3][21] - **Sales Expectations**: Peak sales for KN026 and KN003 could reach 5 billion CNY, with production capacity ensuring supply for at least 1.5 million units of KN026 [19][27] Regulatory and Certification Achievements - **Regulatory Milestones**: Six certifications from domestic and international authorities in 2025, including multiple BTD and orphan drug designations for KN003 [4][27] Future Milestones - **2026 Milestones**: - H1: Launch of KN026 for breast cancer, new data for gastric cancer, and initiation of KN003 colorectal cancer trials [17][27] - H2: Submission of KN026 for breast cancer, data readout for KN003, and initiation of KN016 trials for non-small cell lung cancer [17][27] Clinical Data and Competitive Landscape - **KN026 vs. Competitors**: Demonstrated superior efficacy in gastric cancer compared to T-DXd and T-DM1, with potential to set new standards in treatment [7][12] - **KN003 in Ovarian Cancer**: ORR of 63.8% in platinum-resistant ovarian cancer, with significant safety advantages over competitors [11][12] Product Synergy - **Complementary Product Strategy**: KN026 and KN003 designed to cover the full lifecycle of HER2-positive breast and gastric cancers, enhancing the company's growth potential [13][19] Research and Development Focus - **Innovative Pipeline**: Focus on dual-target ADCs and novel payloads, with ongoing exploration of new mechanisms and clinical applications [26][27] Additional Important Information - **Market Dynamics**: The company is preparing for competitive pressures from established therapies and generics, emphasizing the need for strong clinical data to support market entry [21][27] - **Long-term Vision**: Commitment to addressing unmet clinical needs while ensuring shareholder returns through innovative product development and strategic partnerships [27]

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 566,235 thousand, a decrease of 11.5% compared to RMB 640,083 thousand in 2024[4] - Gross profit for the same period was RMB 502,689 thousand, down from RMB 579,767 thousand in 2024, reflecting a gross margin decline[4] - The company reported a loss before tax of RMB 113,939 thousand for 2025, compared to a profit of RMB 166,342 thousand in 2024[4] - The company recorded a net loss of RMB 113.9 million for the year ended December 31, 2025, compared to a profit of RMB 166.3 million in 2024[57] - The total cost of sales for the year ended December 31, 2025, was RMB 63.5 million, compared to RMB 60.3 million for the year ended December 31, 2024[19] - The company recorded other income of RMB 52.8 million for the year ended December 31, 2025, down from RMB 62.0 million for the year ended December 31, 2024[19] - The revenue from pharmaceutical sales and licensing fees for the year ended December 31, 2025, was RMB 130.1 million, a decrease from RMB 159.5 million for the year ended December 31, 2024[21] - Licensing fee income for the year ended December 31, 2025, was RMB 412.5 million, down from RMB 464.2 million for the year ended December 31, 2024[21] Research and Development - Research and development expenses increased significantly to RMB 572,161 thousand, up 41.5% from RMB 404,152 thousand in 2024, indicating a strong focus on innovation[4] - The company achieved significant milestones in its drug pipeline, including the initiation of multiple clinical trials for new treatments in 2025[7] - JSKN003 received approval for a Phase III clinical trial for HER2+ breast cancer patients, with the first patient dosed in February 2025[7] - The Phase II clinical trial results for KN026 combined with KN046 in HER2+ breast cancer were published in Clinical Cancer Research in June 2025[8] - The company completed patient enrollment for several key clinical trials, indicating progress in its clinical development strategy[8] - JSKN003 received breakthrough therapy designation from the CDE for treating HER2+ advanced colorectal cancer patients previously treated with oxaliplatin, fluorouracil, and irinotecan[10] - JSKN003's Phase III clinical trial for HER2+ advanced colorectal cancer commenced, marking the fourth Phase III study for this drug[10] - KN035 received orphan drug designation from the FDA for treating gastric cancer/gastroesophageal junction cancer, following previous designations in other cancer types[11] - JSKN022's IND application for treating advanced solid tumors was accepted by the CDE, marking the company's fourth ADC entering clinical research[10] - The company’s strong R&D capabilities are supported by proprietary technology platforms in ADCs and bispecific antibodies[14] - The company’s product pipeline includes multiple candidates in various stages of clinical trials, with several products already approved by the National Medical Products Administration[15] Assets and Liabilities - Non-current assets decreased to RMB 503,284 thousand from RMB 530,406 thousand in 2024, while current assets also fell to RMB 1,593,783 thousand from RMB 1,711,349 thousand[6] - Cash and cash equivalents decreased from RMB 1,112.1 million as of December 31, 2024, to RMB 258.8 million as of December 31, 2025, while time deposits with maturities over three months increased from RMB 459.3 million to RMB 1,091.5 million during the same period[41] - Trade receivables rose significantly to RMB 66.5 million as of December 31, 2025, from RMB 16.5 million as of December 31, 2024, mainly due to increased license fee income recognized during the reporting period[37] - Total liabilities decreased from RMB 155,827,000 in 2024 to RMB 105,324,000 in 2025, a reduction of 32.5%[60] - The company's net asset value was RMB 1,710,898,000 in 2025, down from RMB 1,831,884,000 in 2024, a decrease of 6.6%[60] - The company reported a significant increase in inventory, rising to RMB 107,884,000 in 2025 from RMB 81,809,000 in 2024, an increase of 31.9%[58] - Trade payables increased to RMB 70,545,000 in 2025 from RMB 39,222,000 in 2024, showing a growth of about 79.9%[96] Operational Highlights - The company was included in the MSCI Global Small Cap Index as of May 2025, enhancing its market visibility[8] - The company was recognized as one of the "Top 100 Innovative Pharmaceutical Enterprises in China" by a professional magazine in November 2025[10] - The company aims to enhance its manufacturing capabilities with new facilities expected to exceed a total capacity of 40,000L[17] - The company plans to focus on ADC (Antibody-Drug Conjugates) in its drug discovery and development efforts to enrich its early pipeline[18] - The company is actively seeking strategic collaboration opportunities to maximize the commercial value of its global patent assets[18] Shareholder Information - The company plans to hold its annual general meeting on June 12, 2026[117] - The company will suspend the transfer of shares from June 9 to June 12, 2026, to determine the eligibility of shareholders to attend the annual general meeting[118] - The annual report for the year ending December 31, 2025, will be made available to shareholders in April 2026[119] - No dividends were declared or proposed for the fiscal year ending December 31, 2025, consistent with 2024[101][102] - The company repurchased a total of 2,767,000 shares as treasury stock during the reporting period, with a total value of up to HKD 50 million authorized for share buybacks[108] Audit and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the financial results for the year ending December 31, 2025[110] - Deloitte Touche Tohmatsu Certified Public Accountants conducted a review of the financial statements, confirming consistency with the audited financial reports[111] Risks and Future Outlook - The company has identified several risks and uncertainties that may adversely affect its business, financial condition, and operating results[116] - The company expresses gratitude to its shareholders, management team, employees, business partners, and customers for their support and contributions[120]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 KN026輔助治療HER2+乳腺癌III期臨床研究完成首例患者給藥 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，旨在知會本集團股東（「股東」）及潛在投資者有關本集團的最新業務發展。 康寧傑瑞生物製藥 本公司董事（「董事」）會（「董事會」）欣然宣佈，與石藥集團有限公司（股份代號： 1093）附屬公司上海津曼特生物科技有限公司合作開發的KN026聯合多西他賽 （白蛋白結合型）(HB1801)和化療輔助治療人表皮生長因子受體2（「HER2」）陽性 （「HER2+」）乳腺癌（「BC」）的一項III期臨床研究（研究編號：KN026-007）已成功 完成首例患者給藥。 BC是中國女性發病率最高的惡性腫瘤，其中HER2+亞型約佔20%至30%。儘管 曲妥珠單抗（聯合或不聯合帕 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 1 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 JSKN016用於治療TNBC的III期臨床研究完成首例患者給藥 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，以知會本集團股東（「股東」）及潛在投資者有關本集團之最新業務進展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，JSKN016（一種靶向滋養層細胞表 面抗原2（「TROP2」）及人表皮生長因子受體3（「HER3」）的雙特異性抗體偶聯藥 物（「ADC(s)」））用於治療三陰性乳腺癌（「TNBC」）的一項III期臨床研究（研究編 號：JSKN016-301）已成功完成首例患者給藥。該里程碑標誌著本公司開發的又一 創新雙抗ADC進入關鍵臨床開發階段，有望為目標患者人群提供更有效、更安全 的ADC治療選擇。 乳腺癌（「BC」）是全球女性 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 本公司謹此宣佈，柴博先生（「柴先生」）因其他工作安排已辭任本公司資本市場部 副總裁，自2026年3月16日起生效。柴先生已確認其與本公司並無意見分歧，亦 無任何有關其辭任之事項須提請聯交所及本公司股東垂注。 自願公告 委任首席財務官 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司統稱「本集團」）自願作 出。 本公司董事（「董事」）會（「董事會」）欣然宣佈，委任王飛先生（「王先生」）為本 公司首席財務官，自2026年3月16日起生效。王先生將主要負責本集團的資本運 作、投融資管理及投資者關係。 王先生的履歷詳情載列如下： 王先生於財務管理及資本市場擁有逾20年經驗，包括於中國及海外生物製藥行業 擁有逾15年經驗。於加入本集團前，王先生曾就職於阿斯利康，於2011年1月至 2015年10月 ...

Core Insights - The article highlights significant developments in the energy storage sector, showcasing various companies securing large-scale contracts for energy storage systems across Europe and South America [3][4][6][7][8][10]. Group 1: Company Contracts and Projects - Sungrow Power Supply has signed a storage cooperation agreement with ENEVO Group in Romania for a total installed capacity of 1GWh, with the first phase involving a 440MWh project to be completed by December 2026 [3]. - LONGi Green Energy has reached strategic cooperation agreements in Europe, securing a total of 600MWh of storage systems and 100MW of anti-glare components [4]. - Canadian Solar's subsidiary, Canadian Solar Energy, has signed a supply agreement for a 500MW/2,493MWh storage project aimed at supporting data center electricity demands, with delivery expected to start in March 2027 [6]. - Huawei Digital Energy has partnered with Aggreko to provide a battery storage system for Brazil's largest microgrid project, with a total investment of approximately 1.1 billion RMB [7]. - Ruipu Lanjun has signed supply agreements for a total of 8.3GWh of storage systems with seven European partners, reinforcing its market position [8]. - Nandu Power has secured a 117MWh storage project in Australia, utilizing its self-developed liquid-cooled storage system [10]. Group 2: Industry Events - The 14th International Energy Storage Summit and Exhibition (ESIE 2026) will take place from March 31 to April 3, 2026, in Beijing, featuring participation from leading companies in the energy storage sector [12].

Group 1 - The article announces the 2026 Lithium Battery Key Materials and Applications Summit, organized by Xinluo Information, scheduled for March 19-20, 2026, in Changzhou, Jiangsu [5][6] - The summit will cover various topics related to lithium carbonate, including risk management, market outlook, and innovative technologies in energy storage [5][6] - Key speakers include representatives from companies such as Donghai Capital, Longpan Technology, and Xiamen International Trade, discussing strategies and market trends in the lithium industry [5][6] Group 2 - The venue for the summit is the Changzhou Wujin Jiuzhou Sheraton Hotel, with accessible transportation options including metro and airport services [3][4] - The agenda includes sessions on lithium carbonate price fluctuations, supply chain impacts, and advancements in energy storage solutions [5][6] - The event aims to facilitate discussions on the challenges and opportunities in the global new energy vehicle market and the development of sodium battery ecosystems [5][6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 JSKN021的IND申請獲CDE正式受理 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，以知會本集團股東（「股東」）及潛在投資者有關本集團之最新業務進展。 於2025年美國癌症研究協會年會發佈的臨床前數據顯示，JSKN021能有效抑制 HER3陽性、EGFR陽性或雙陽性腫瘤細胞的生長。此外，在多種CDX模型中， JSKN021的腫瘤抑制效果顯著優於單載荷ADC藥物。有關進一步詳情，請參閱本 公司日期為2025年4月30日的公告。 關於JSKN021 JSKN021是一款全球首創的雙抗雙載荷ADC，由靶向EGFR/HER3雙特異性抗體 與新型拓撲異構酶I抑制劑（「T01」）及甲基澳瑞他汀E（「MMAE」）偶聯而成。該 藥物通過精確調控雙抗結合親和 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） 徐霆博士 董事長兼執行董事 於本公告日期，董事會包括董事長兼執行董事徐霆博士及執行董事劉陽女士；非 執行董事左敏先生；及獨立非執行董事吳冬先生、黃欣琪女士及高翔博士。 （股份代號：9966） 香港，2026年3月11日 董事會會議日期 康寧傑瑞生物製藥（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將 於2026年3月25日（星期三）舉行董事會會議，藉以（其中包括）考慮及通過本公司 及其附屬公司截至2025年12月31日止年度之年度業績及其發佈，以及處理其他事 項。 承董事會命 康寧傑瑞生物製藥 ...